Drug Profile
Tarcocimab tedromer - Kodiak Sciences
Alternative Names: KSI-301Latest Information Update: 08 May 2024
Price :
$50
*
At a glance
- Originator Oligasis
- Developer Kodiak Sciences
- Class Antibodies; Biopolymers; Drug conjugates; Eye disorder therapies; Immunoconjugates
- Mechanism of Action Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Diabetic macular oedema; Diabetic retinopathy; Retinal vein occlusion; Wet age-related macular degeneration